Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
醫療保健板塊中最超賣的股票爲買入被低估的公司提供了機會。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
RSI指標是一種動量指標，它比較了股票在價格上漲時的強度與在價格下跌時的強度。與股票的價格走勢進行比較，可以給交易者更好的了解股票短期內表現的良好程度。當RSI低於30時，資產通常被認爲是超賣的，根據Benzinga Pro的數據。
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
以下是本行業板塊最近的主要超賣股票列表，RSI接近或低於30。
Organon & Co (NYSE:OGN)
Organon & Co (紐交所:OGN)
- Organon will release its third quarter 2024 financial results on Oct. 31. The company's stock fell around 12% over the past month and has a 52-week low of $10.84.
- RSI Value: 28.28
- OGN Price Action: Shares of Organon fell 0.9% to close at $17.45 on Monday.
- Benzinga Pro's real-time newsfeed alerted to latest OGN news.
- Organon將於2024年10月31日公佈第三季度業績。該公司股價在過去一個月下跌了約12%，並且52周內最低價爲10.84美元。
- RSI數值: 28.28
- OGN股價走勢: Organon的股價週一下跌0.9%，收於17.45美元。
- Benzinga Pro的實時新聞提醒了最新的OGN資訊。
Arcutis Biotherapeutics Inc (NASDAQ:ARQT)
arcutis biotherapeutics公司（納斯達克：ARQT）
- On Oct. 21, Arcutis Canada announced Health Canada approval of ZORYVE Foam to treat seborrheic dermatitis in individuals 9 years of age and older. Dr. Melinda Gooderham, medical director at the SKiN Centre for Dermatology and a principal Canadian investigator in the pivotal Phase 3 STRATUM trial said, "The approval of ZORYVE foam by Health Canada is a significant development in the management of this condition. Clinical trial data show close to 80% of patients achieving treatment success at week 8 and rapid itch relief in as little as 48 hours." The company's stock fell around 14% over the past five days and has a 52-week low of $1.76.
- RSI Value: 28.13
- ARQT Price Action: Shares of Arcutis Biotherapeutics fell 4.7% to close at $8.31 on Monday.
- Benzinga Pro's charting tool helped identify the trend in ARQT stock.
- 10月21日，Arcutis加拿大宣佈獲得衛生加拿大批准將ZORYVE泡沫用於治療9歲及以上個體的脂溢性皮炎。SKiN皮膚病診所的醫學董事Melinda Gooderham博士是關鍵的加拿大研究者之一，在關鍵的第3期STRATUm試驗中表示：「衛生加拿大批准ZORYVE泡沫是這種控件管理中的重要進展。臨床試驗數據顯示，近80%的患者在第8周時取得治療成功，而且在48小時內就可以快速緩解瘙癢。」該公司股價在過去五天內下跌了大約14%，並且低至52周的最低價格爲1.76美元。
- RSI數值：28.13
- ARQt價格波動：Arcutis Biotherapeutics的股票下跌了4.7%，週一收盤價爲8.31美元。
- Benzinga Pro的圖表工具幫助確定了ARQt股票的趨勢。
TransMedics Group Inc (NASDAQ:TMDX)
TransMedics Group公司（納斯達克：TMDX）
- TransMedics Group will release financial results for the third quarter after market close on Monday, Oct. 28. The company's shares fell around 22% over the past month and has a 52-week low of $36.42.
- RSI Value: 29.60
- TMDX Price Action: Shares of TransMedics fell 1.7% to close at $124.48 on Monday.
- Benzinga Pro's signals feature notified of a potential breakout in TMDX shares.
- transmedics集團將於10月28日週一盤後發佈第三季度財務業績。該公司股價在過去一個月下跌了約22%，52周最低價爲36.42美元。
- RSI數值：29.60
- transmedics股票價格走勢：transmedics股票週一下跌1.7%，收盤價爲124.48美元。
- Benzinga Pro的信號功能通知transmedics股票可能出現突破。
Read More:
閱讀更多：
- This Analyst With 85% Accuracy Rate Sees Around 11% Upside In Netflix – Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts
- 這位準確率達85%的分析師預計奈飛股票有大約11%的上漲空間 - 這裏是華爾街最準確分析師上週的5只股票推薦。
譯文內容由第三人軟體翻譯。
